Evidence map›Paper›PMID 36052609›Full record

ArticleThe Journal of infectious diseases2022

A Composite Recombinant Salivary Proteins Biomarker for Phlebotomus argentipes Provides a Surveillance Tool Postelimination of Visceral Leishmaniasis in India.

Eva Iniguez, Samiran Saha, Georgios Petrellis, Claudio Menenses, Samantha Herbert, Yvonne Gonzalez-Rangel, Tobin Rowland, Naomi E Aronson, Clair Rose, Lee Rafuse Haines and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Comparative Analysis ofMicroorganisms · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Eva IniguezVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Samiran SahaDepartment of Biotechnology, Institute of Science, Visva Bharati University, Bolpur, West Bengal, India.
Georgios PetrellisVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Claudio MenensesVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Samantha HerbertVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Yvonne Gonzalez-RangelVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Tobin RowlandEntomology Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Naomi E AronsonInfectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Clair RoseDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Lee Rafuse HainesDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Alvaro Acosta-SerranoDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Tiago D SerafimVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Fabiano OliveiraVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-7924-8038
Sridhar SrikantiahBihar Technical Support Program, CARE India Solutions for Sustainable Development, Patna, India.
Caryn BernDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jesus G ValenzuelaVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Shaden KamhawiVector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
National Institutes of Health · USLiverpool School of Tropical Medicine · GBCare India · INUniformed Services University of the Health Sciences · USUniversity of California, San Francisco · USVisva-Bharati University · INWalter Reed Army Institute of Research · US

Funding

NIAID NIH HHS
6 · The paper itself

Abstract

Incidence of visceral leishmaniasis (VL) in the Indian subcontinent (ISC) has declined by more than 95% since initiation of the elimination program in 2005. As the ISC transitions to the postelimination surveillance phase, an accurate measurement of human-vector contact is needed to assure long-term success. To develop this tool, we identified PagSP02 and PagSP06 from saliva of Phlebotomus argentipes, the vector of Leishmania donovani in the ISC, as immunodominant proteins in humans. We also established the absence of cross-reactivity with Phlebotomus papatasi saliva, the only other human-biting sand fly in the ISC. Importantly, by combining recombinant rPagSP02 and rPagSP06 we achieved greater antibody recognition and specificity than single salivary proteins. The receiver operating characteristics curve for rPagSP02 + rPagSP06 predicts exposure to Ph. argentipes bites with 90% specificity and 87% sensitivity compared to negative control sera (P >.0001). Overall, rPagSP02 + rPagSP06 provides an effective surveillance tool for monitoring vector control efforts after VL elimination.

Indexed as

Leishmania donovaniLeishmaniasis, VisceralPhlebotomusAnimalsBiomarkersHumansIndiaSalivary Proteins and PeptidesBiomarkersSalivary Proteins and Peptidesbiomarkerelimination campaignIndiaPhlebotomus argentipessand fly salivary proteinssurveillancevisceral leishmaniasis

Identifiers

PMID36052609
PMCPMC10205619
OpenAlexW4294225502

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.